Dieci MV - Search Results

1

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer. Dieci MV, et al. Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Semin Cancer Biol. 2018. PMID: 29024776 Free article. Review.

2

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Andre F, et al. Among authors: dieci mv. Clin Cancer Res. 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. Clin Cancer Res. 2013. PMID: 23258741 Review.

3

Landscape and evolution of therapeutic research for breast cancer patients.

Dogan S, Dieci MV, Goubar A, Arnedos M, Delaloge S, Andre F. Dogan S, et al. Among authors: dieci mv. Breast Cancer Res Treat. 2013 Feb;138(1):319-24. doi: 10.1007/s10549-013-2436-y. Epub 2013 Feb 14. Breast Cancer Res Treat. 2013. PMID: 23408207

4

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Guarneri V, et al. Among authors: dieci mv. Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7. Ann Oncol. 2013. PMID: 24013581 Free article.

5

Quantification of residual risk of relapse in breast cancer patients optimally treated.

Dieci MV, Arnedos M, Delaloge S, Andre F. Dieci MV, et al. Breast. 2013 Aug;22 Suppl 2:S92-5. doi: 10.1016/j.breast.2013.07.017. Breast. 2013. PMID: 24074801 Free article. Review.

6

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401929 Free PMC article.

7

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.

Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A. Dieci MV, et al. Ann Oncol. 2015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20. Ann Oncol. 2015. PMID: 25995301 Free PMC article. Clinical Trial.

8

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. Ann Oncol. 2015. PMID: 26109735 Free PMC article. No abstract available.

9

The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

Dieci MV, Griguolo G, Miglietta F, Guarneri V. Dieci MV, et al. Cancer Treat Rev. 2016 May;46:9-19. doi: 10.1016/j.ctrv.2016.03.011. Epub 2016 Mar 28. Cancer Treat Rev. 2016. PMID: 27055087 Review.

10

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Dieci MV, et al. Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Breast Cancer Res Treat. 2017. PMID: 28289852

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169 results

Search Page